Completed NA INTERVENTIONAL 1-arm NCT00118508

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

Sponsor: Aventis Pharmaceuticals

Interventions risedronate (including placebo)

Updated 6 times since 2017 Last updated: Aug 10, 2015 Started: May 31, 2003 Primary completion: Jul 31, 2006 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00118508, this NA trial focuses on Osteoporosis and remains completed. Sponsored by Aventis Pharmaceuticals, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aventis Pharmaceuticals
Procter and Gamble
University of Pittsburgh

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States